The Quantellect read.As of Nov 19, 2026, 7 active firms cover Cogent Biosciences Inc: 6 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $52.00 to $67.00, so the covering firms are broadly aligned. The average target of $56.50 sits 103% above the current $27.82. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.53 next quarter toward $-1.29 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy686%
Neutral114%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$56.50
+103.1% upside
Average target across 6 active firms as of Nov 19, 2026 vs $27.82 current
Highest Target$67.00
Average Target$56.50
Lowest Target$52.00
Detailed analyst forecasts for COGT
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 6 of 7 active firms rate COGT a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
COGT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.53
Range $-0.56 – $-0.51 · 3 analysts · +0% YoY
Next period, 3 analysts expect Cogent Biosciences Inc to earn $-0.53 a share (range $-0.56 – $-0.51), versus $-0.53 a year earlier. Full-year consensus is $-2.33, growing to $-1.29 the year after.
REVENUE · NEXT QUARTER
$29.3M
Range $7.2M – $41.0M · 3 analysts
Revenue is expected to reach $29.3M (range $7.2M – $41.0M). Full-year consensus is $5.2M, rising to $279.8M next year.
Top analysts covering Cogent Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on COGT.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$52.00+86.9% to target
Overall win rate
53%
+ Follow
#2
David Nierengarten
Wedbush · Rank #24
Buy
$55.00+97.7% to target
Overall win rate
48%
+ Follow
#3
Joel Beatty
Baird · Rank #71
Neutral
$9.00-67.6% to target
Overall win rate
50%
+ Follow
#4
Ami Fadia
Needham · Rank #92
Neutral
No targeton COGT
Overall win rate
46%
+ Follow
#5
Andrew Berens
Leerink Partners · Rank #162
Buy
$50.00+79.7% to target
Overall win rate
53%
+ Follow
COGT stock forecast FAQ
What is COGT's average 12-month price target?+
The 6 active firms with a live target average $56.50 for Cogent Biosciences Inc over the next 12 months, ranging from a $67.00 high to a $52.00 low, as of Nov 19, 2026.
Is COGT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for COGT?+
The Street-high target is $67.00 (JP Morgan), and the Street-low is $52.00 (Guggenheim). The average of all 6 active-firm targets is $56.50.
How many active Wall Street firms cover COGT?+
7 active firms have a recognized rating on Cogent Biosciences Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering COGT?+
Among analysts who currently cover COGT, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $52.00 target.
What is Cogent Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.53 per share (range $-0.56 – $-0.51) across 3 analysts. Full-year EPS is projected at $-2.33, rising to $-1.29 the following year.
How much revenue is Cogent Biosciences Inc expected to report next quarter?+
Consensus revenue is $29.3M (range $7.2M – $41.0M). Full-year revenue is projected at $5.2M, growing to $279.8M next year.
Have analysts been upgrading or downgrading COGT lately?+
As of Nov 19, 2026, 6 of 7 active firms rate COGT a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their COGT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.